Clinical, molecular and geographical features of hereditary breast/ovarian cancer in Latvia

Hereditary Cancer in Clinical Practice

Volumn 3, Issue 2, 2005, Pages 71-76

  Gardovskis, Andris ^a   Irmejs, Arvids ^a   Milosevics, Edvins ^a   Borosenko, Viktors ^a   Bitina, Marianna ^a   Melbarde Gorkusa, Inga ^a   Vanags, Andrejs ^a   Kurzawski, Grzegorz ^b   Suchy, Janina ^b   Górski, Bohdan ^b   Gardovskis, Janis ^a  

^a RIGA STRADINS UNIVERSITY   (Latvia)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Breast ovarian cancer; Hereditary

Indexed keywords

BRCA1 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL FEATURE; CONTROLLED STUDY; EXON; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INCIDENCE; LATVIA; MAJOR CLINICAL STUDY; OVARY CANCER;

EID: 22144478275     PISSN: 17312302     EISSN: None     Source Type: Journal    
DOI: 10.1186/1897-4287-3-2-71     Document Type: Article

References (14)

1. Jacobi CE, Jonker MA, Nagelkerke NJD, van Houwelingen JC and de Bock GH. Prevalence of family histories of breast cancer in the general population and the incidence of related seeking of health care. J Med Genet 2003; 40: e83.
2. Hereditair Mamma (Ovarium) Carcinoom. In: Erfelijke tumoren. Richtlijnen voor diagnostiek en preventie. Stichting Opsporing Erfelijke Tumoren&Vereniging Klinische Genetica Nederland, Werkgroep Klinische Oncogenetica 2001; 7-13.
3. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62: 676-689.
4. Levine DA and Gemignani ML. Prophylactic surgery in hereditary breast/ovarian cancer syndrome. Oncology 2003; 17(7): 932-952.
5. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG and Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72 (5): 1117-1130.
6. McPherson K, Steel CM and Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 2000; 321: 624-628.
7. Csokay B, Tihomirova L, Stengrevics A, Sinicka O and Olah E. Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia. Mutation in brief no. 258. Hum Mutat 1999; 14 (1): 92.
8. Moller P, Borg A, Evans DG, Haites N, Reis MM, Vasen H, Anderson E, Steel CM, Apold J, Goudie D, Howell A, Lalloo F, Maehle L, Gregory H and Heimdal K. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 2002; 101 (6): 555-559.
9. Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B and Klijn JG. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 2003; 21 (9): 1675-1681.
10. Zeigler LD and Kroll SS. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 1991; 14: 451-453.
11. Bergthorsson JT, Ejlertsen B, Olsen JH, Borg A, Nielsen KV, Barkardottir RB, Klausen S, Mouridsen HT, Winther K, Fenger K, Niebuhr A, Harboe TL and Niebuhr E. BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age. J Med Genet 2001; 38 (6): 361-368.
12. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL; Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346 (21): 1616-1622.
13. Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Evans G, Osborne M, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P and Brunet JS. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002; 94 (23): 1773-1779.
14. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H; Hereditary Breast Cancer Clinical Study Group. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000; 356: 1876-1881.